Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 801–900 of 1,014
Thiazolidinediones on PPAR γ : The Roles in Bone Remodeling
Wei, W., & Wan, Y. (2011) · PPAR Research · doi:10.1155/2011/867180 · Cited by 59
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
Bouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51
Bone metabolism in type 2 diabetes and role of thiazolidinediones
Vestergaard, P. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328325d155 · Cited by 53
Osteoporosis and Fracture Risk in Patients with Type 2 Diabetes Mellitus
Poiană, C., & Capatina, C. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.231 · Cited by 52
Viscoli, C. M., Brass, L. M., Carolei, A., Conwit, R., Ford, G. A., Furie, K. L., Gorman, M., Guarino, P. D., Inzucchi, S. E., Lovejoy, A. M., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.016 · Cited by 50
Ito, H., Ishida, H., Takeuchi, Y., Antoku, S., Abe, M., Mifune, M., & Togane, M. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-83 · Cited by 50
Souza-Tavares, H., Miranda, C. S., Vasques‐Monteiro, I. M. L., Sandoval, C., Santana-Oliveira, D. A., Silva-Veiga, F. M., Fernandes‐da‐Silva, A., & Souza‐Mello, V. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i26.4136 · Cited by 54
Overview of Metformin and Neurodegeneration: A Comprehensive Review
Kruczkowska, W., Gałęziewska, J., Buczek, P., Płuciennik, E., Kciuk, M., & Śliwińska, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040486 · Cited by 58
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
Hanefeld, M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01361.x · Cited by 57
The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
Rotenstein, L. S., Kozak, B. M., Shivers, J. P., Yarchoan, M. M., Close, J., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.2.44 · Cited by 56
Review article: Thiazolidinediones and heart failure
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338772 · Cited by 50
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
Carta, A. R., Pisanu, A., & Carboni, E. (2011) · Parkinson s Disease · doi:10.4061/2011/689181 · Cited by 60
Arakaki, R. F. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1167570 · Cited by 61
Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ
Heidari, Z., Chrisman, I. M., Nemetchek, M. D., Novick, S. J., Blayo, A., Patton, T. M., Mendes, D. E., Diaz, P., Kamenecka, T. M., Griffin, P. R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13768-0 · Cited by 52
Polonsky, K. S., & Burant, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00031-9 · Cited by 73
Whitticar, N. B., & Nunemaker, C. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00378 · Cited by 56
Bhattacharyya, O. K., Shah, B. R., & Booth, G. L. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080554 · Cited by 52
Cardiovascular safety of rosiglitazone
Krall, R. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60824-1 · Cited by 50
Moses, R. G., Kalra, S., Brook, D., Sockler, J., Monyak, J., Visvanathan, J., Montanaro, M., & Fisher, S. A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12234 · Cited by 49
Nichols, G. A., Conner, C., & Brown, J. B. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.504396 · Cited by 49
Obesity, diabetes mellitus and last but not least, osteoporosis
de Paula, F. J. A., & Rosen, C. J. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200010 · Cited by 57
Gruntmanis, U., Fordan, S., Ghayee, H. K., Abdullah, S. M., See, R., Ayers, C. R., & McGuire, D. K. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9352-5 · Cited by 49
Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4202 · Cited by 48
Wilding, J. P. H., Godec, T. R., Khunti, K., Pocock, S., Fox, R. A., Smeeth, L. L., Clauson, P., Fenici, P., Hammar, N., & Medina, J. (2018) · BMC Medicine · doi:10.1186/s12916-018-1085-8 · Cited by 55
Metabolic syndrome: A predictor of adverse outcomes after carotid revascularization
Protack, C. D., Bakken, A. M., Xu, J., Saad, W. A., Lumsden, A. B., & Davies, M. G. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.12.011 · Cited by 49
The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
Pi-Sunyer, F. X. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1785 · Cited by 49
Remillard, C., MacConell, Li, Pencek, Maggs, & Porter (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s35801 · Cited by 50
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease
Wagner, N., & Wagner, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032345 · Cited by 52
Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium
Nathanson, D., & Nyström, T. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.016 · Cited by 53
Lebovic, D. I., Mwenda, J. M., Chai, D. C., Santi, A., Xu, X., & D'Hooghe, T. (2010) · Endocrinology · doi:10.1210/en.2009-1076 · Cited by 47
van Dieren, S., Czernichow, S., Chalmers, J., Kengne, A. P., de Galan, B. E., Poulter, N., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01556.x · Cited by 50
Kuriyama, C., Xu, J., Lee, S. P., Qi, J., Kimata, H., Kakimoto, T., Nakayama, K., Watanabe, Y., Taniuchi, N., Hikida, K., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.217992 · Cited by 48
Investigational insulin secretagogues for type 2 diabetes
Scheen, A. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152260 · Cited by 53
Dludla, P. V., Nyambuya, T. M., Johnson, R., Silvestri, S., Orlando, P., Mazibuko-Mbeje, S. E., Gabuza, K., Mxinwa, V., Mokgalaboni, K., Tiano, L., et al. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09942-y · Cited by 50
Sam, S., Edelstein, S. L., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Ehrmann, D. A., Hannon, T. S., Tjaden, A. H., Kahn, S. E., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0027 · Cited by 50
Self-citationTop, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 54
Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Hossain, M. A., & Pervin, R. (2018) · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome · doi:10.1016/b978-0-12-812019-4.00034-9 · Cited by 47
Erhardt, W., Bergenheim, K., Duprat-Lomon, I., & McEwan, P. C. (2012) · Clinical Drug Investigation · doi:10.2165/11597060-000000000-00000 · Cited by 49
The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels, K. B., & van Grootheest, K. (2012) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2012-0559 · Cited by 53
Anjana, R. M., Shanthirani, C. S., Unnikrishnan, R., Poongkunran, M., Amutha, A., Nair, H. D., Subhashini, S., Venkatesan, U., Ali, M. K., Ranjani, H., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0701-0 · Cited by 52
Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents
Datar, P. A., & Aher, S. B. (2012) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2012.10.010 · Cited by 54
Biomarkers and immune-modulating therapies for Type 2 diabetes
Brooks‐Worrell, B., Narla, R. R., & Palmer, J. P. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.002 · Cited by 50
Carpino, P. A., & Goodwin, B. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.533171 · Cited by 54
Hypoglycaemia: current management and controversies
Choudhary, P., & Amiel, S. A. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.068197 · Cited by 47
Glibenclamide improves neurological function in neonatal hypoxia–ischemia in rats
Zhou, Y., Fathali, N., Lekic, T., Tang, J., & Zhang, J. H. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.010 · Cited by 49
Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, J. L., Menéndez, S. A., NúñezfiCortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65006-5 · Cited by 61
Diabetes Drug Effects on the Skeleton
Chandran, M. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0203-x · Cited by 48
Lan, Y. T., Kuang, Y. P., Zhou, L. P., Wu, G. Y., Gu, P. C., Wei, H. J., & Chen, K. (2017) · Laser Physics Letters · doi:10.1088/1612-202x/aa58c0 · Cited by 47
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.357 · Cited by 54
Treatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 54
Wu, S., Gao, L., Cipriani, A., Huang, Y., Yang, Z., Yang, J., Yu, S., Zhang, Y., Chai, S., Zhang, Z., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13613 · Cited by 48
Nicolucci, A., Charbonnel, B. H., Gomes, M. B., Khunti, K., Kosiborod, M., Shestakova, M. V., Shimomura, I., Watada, H., Chen, H., Cid‐Ruzafa, J., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13830 · Cited by 48
Mearns, E. S., Saulsberry, W. J., White, C. M., Kohn, C. G., Lemieux, S., Sihabout, A., Salamucha, I., & Coleman, C. I. (2015) · Diabetic Medicine · doi:10.1111/dme.12837 · Cited by 46
Dawed, A. Y., Yee, S. W., Zhou, K., van Leeuwen, N., Zhang, Y., Siddiqui, M. K., Etheridge, A. S., Innocenti, F., Xu, F., Li, J. H., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1152 · Cited by 46
Self-citationGoyal, S., Rani, J., Bhat, M. A., & Vanita, V. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.656 · Cited by 53
Factors Associated with Beta-Cell Dysfunction in Type 2 Diabetes: The BETADECLINE Study
Russo, G. T., Giorda, C. B., Cercone, S., Nicolucci, A., Cucinotta, D., & on behalf of BetaDecline Study Group (2014) · PLoS ONE · doi:10.1371/journal.pone.0109702 · Cited by 49
ERDMANN, E., SPANHEIMER, R., CHARBONNEL, B., & on behalf of the PROactive Study Investigators (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00082.x · Cited by 46
Dietz, M., Mohr, P., Kuhn, B., Maerki, H. P., Hartman, P., Ruf, A., Benz, J., Grether, U., & Wright, M. B. (2012) · ChemMedChem · doi:10.1002/cmdc.201100598 · Cited by 47
Singh, S., Loke, Y. K., & Furberg, C. D. (2011) · Thorax · doi:10.1136/thx.2010.152777 · Cited by 51
Pharmacogenetics and personalized treatment of type 2 diabetes
Semiz, S., Dujić, T., & Čaušević, A. (2013) · Biochemia Medica · doi:10.11613/bm.2013.020 · Cited by 54
Abrahamson, M. J. (2014) · Diabetes Care · doi:10.2337/dc14-1945 · Cited by 47
van der Veen, J. N., Lingrell, S., Gao, X., Quiroga, A. D., Takawale, A. R., Armstrong, E. A., Yager, J. Y., Kassiri, Z., Lehner, R. S., Vance, D. E., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2015 · Cited by 55
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
Metformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 49
Pistrosch, F., Köhler, C. U., Schäper, F., Landgraf, W., Forst, T. M., & Hanefeld, M. (2013) · Acta Diabetologica · doi:10.1007/s00592-012-0451-9 · Cited by 48
Cefalu, W. T., Waldman, S. A., & Ryder, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100156 · Cited by 56
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
Hamed, E. A., Zakary, M. M., Ahmed, N. S., & Gamal, R. M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.08.023 · Cited by 49
Andleeb, H., Tehseen, Y., Shah, S. J. A., Khan, I. A., Iqbal, J., & Hameed, S. (2016) · RSC Advances · doi:10.1039/c6ra14531k · Cited by 45
Tanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 47
Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus
Shao, H., Chen, G., Zhu, C., Chen, Y., Liu, Y., He, Y., & Jin, H. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s92533 · Cited by 45
Monami, M., Liïstro, F., Scatena, A., Nreu, B., & Mannucci, E. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13221 · Cited by 53
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 55
Hollander, P., Hill, J., Johnson, J., Wei Jiang, Z., Golm, G., Huyck, S., Terra, S. G., Mancuso, J. P., Engel, S. S., Lauring, B., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1583450 · Cited by 45
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Adeshara, K. A., Bangar, N. S., Doshi, P. R., Diwan, A. G., & Tupe, R. S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.036 · Cited by 56
Gestational Diabetes During and After Pregnancy
Kim, C., & Ferrara, A. M. (2010) · Springer eBooks · doi:10.1007/978-1-84882-120-0 · Cited by 54
Georgiadis, I., Karatzas, T., Κορού, Λ.-Μ., Katsilambros, N. L., & Perrea, D. N. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2014.0021 · Cited by 50
Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. ‐., & Vaag, A. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00713.x · Cited by 44
Waking up from the DREAM of preventing diabetes with drugs
Montori, V. M., Isley, W. L., & Guyatt, G. H. (2007) · BMJ · doi:10.1136/bmj.39169.447488.94 · Cited by 45
Antidiabetic drugs and kidney disease
Zanchi, A., Lehmann, R., & Philippé, J. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13629 · Cited by 45
2022 Guidelines on the management of patients with diabetes. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2022) · Current Topics in Diabetes · doi:10.5114/ctd/146259 · Cited by 69
Berberoglu, Z., Yazici, A. C., & Demirag, N. G. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03784.x · Cited by 44
Wharton, S., Sharma, A. M., & Lau, D. C. W. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.025 · Cited by 54
Wilding, J. P. H., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.040 · Cited by 45
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
Mamza, J., Mehta, R., Donnelly, R., & Idris, I. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1157263 · Cited by 44
Abdelgadir, E., Ali, R., Rashid, F., & Bashier, A. M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2922e · Cited by 48
Wexler, D. J., Krause-Steinrauf, H., Crandall, J. P., Florez, H. J., Hox, S. H., Kuhn, A., Sood, A., Underkofler, C., Aroda, V. R., GRADE Research Group, et al. (2019) · Diabetes Care · doi:10.2337/dc19-0901 · Cited by 44
Yaturu, S. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00049.x · Cited by 51
DPP-4 Inhibitors in Clinical Practice
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2079 · Cited by 44
HDAC7 Inhibits Osteoclastogenesis by Reversing RANKL-Triggered β-Catenin Switch
Jin, Z., Wei, W., Dechow, P. C., & Wan, Y. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1302 · Cited by 44
von Bibra, H., Diamant, M., Scheffer, P. G., Siegmund, T., & Schumm‐Draeger, P. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.045 · Cited by 45
Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0793 · Cited by 43
New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Green, J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3105 · Cited by 42
Vaccaro, O., Masulli, M., Bonora, E., Prato, S. D., Giorda, C. B., Maggioni, A. P., Mocarelli, P., Nicolucci, A., Rivellese, A. A., Squatrito, S., et al. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.09.003 · Cited by 47
Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective
Khanderia, U., Pop‐Busui, R., & Eagle, K. A. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k666 · Cited by 46
Cheng, D., Gao, H. T., & Li, W. (2018) · Endokrynologia Polska · doi:10.5603/ep.a2018.0036 · Cited by 47
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.